512 related articles for article (PubMed ID: 15776342)
1. The World Anti-Doping Code 2003--consequences for physicians associated with elite athletes.
Striegel H; Rössner D; Simon P; Niess AM
Int J Sports Med; 2005 Apr; 26(3):238-43. PubMed ID: 15776342
[TBL] [Abstract][Full Text] [Related]
2. World anti-doping regulations for 2005: essential changes for athletes and physicians.
Pabinger C; Gruber G
Arch Orthop Trauma Surg; 2006 May; 126(4):286-8. PubMed ID: 16333634
[TBL] [Abstract][Full Text] [Related]
3. [Medication, athletes and doping regulations].
Hartgens F
Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
[TBL] [Abstract][Full Text] [Related]
4. [Medicolegal aspects of doping in sports].
Pruvost J; Depiesse F
Ann Readapt Med Phys; 2004 Aug; 47(6):263-73. PubMed ID: 15297116
[TBL] [Abstract][Full Text] [Related]
5. [World Football Championship 2006--anti-doping regulations].
Wolfarth B; Graf-Baumann T; Halle M
MMW Fortschr Med; 2006 Jun; 148(23):41-3. PubMed ID: 16826737
[TBL] [Abstract][Full Text] [Related]
6. The world anti-doping program and the primary care physician.
Hilderbrand RL
Pediatr Clin North Am; 2007 Aug; 54(4):701-11, x-xi. PubMed ID: 17723872
[TBL] [Abstract][Full Text] [Related]
7. The asthmatic athlete: inhaled Beta-2 agonists, sport performance, and doping.
McKenzie DC; Fitch KD
Clin J Sport Med; 2011 Jan; 21(1):46-50. PubMed ID: 21200170
[TBL] [Abstract][Full Text] [Related]
8. Anti-doping Policy, Therapeutic Use Exemption and Medication Use in Athletes with Asthma: A Narrative Review and Critical Appraisal of Current Regulations.
Allen H; Backhouse SH; Hull JH; Price OJ
Sports Med; 2019 May; 49(5):659-668. PubMed ID: 30887312
[TBL] [Abstract][Full Text] [Related]
9. Ergogenic effects of inhaled beta2-agonists in non-asthmatic athletes.
Wolfarth B; Wuestenfeld JC; Kindermann W
Endocrinol Metab Clin North Am; 2010 Mar; 39(1):75-87, ix. PubMed ID: 20122451
[TBL] [Abstract][Full Text] [Related]
10. Sports physicians, ethics and antidoping governance: between assistance and negligence.
Dikic N; McNamee M; Günter H; Markovic SS; Vajgic B
Br J Sports Med; 2013 Jul; 47(11):701-4. PubMed ID: 23322892
[TBL] [Abstract][Full Text] [Related]
11. Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.
Nikolopoulos DD; Spiliopoulou C; Theocharis SE
Fundam Clin Pharmacol; 2011 Oct; 25(5):535-63. PubMed ID: 21039821
[TBL] [Abstract][Full Text] [Related]
12. Treating the elite athlete: anti-doping information for the health professional.
Tandon S; Bowers LD; Fedoruk MN
Mo Med; 2015; 112(2):122-8. PubMed ID: 25958657
[TBL] [Abstract][Full Text] [Related]
13. The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.
Di Luigi L; Pigozzi F; Sgrò P; Frati L; Di Gianfrancesco A; Cappa M
J Endocrinol Invest; 2020 May; 43(5):563-573. PubMed ID: 31734891
[TBL] [Abstract][Full Text] [Related]
14. Doping control from a global and national perspective.
Fraser AD
Ther Drug Monit; 2004 Apr; 26(2):171-4. PubMed ID: 15228160
[TBL] [Abstract][Full Text] [Related]
15. London 2012: prescribing for athletes in ophthalmology.
Nicholson RG; Thomas GP; Potter MJ; Norris JH
Eye (Lond); 2012 Aug; 26(8):1036-8. PubMed ID: 22744394
[TBL] [Abstract][Full Text] [Related]
16. Hormone abuse in sports: the antidoping perspective.
Barroso O; Mazzoni I; Rabin O
Asian J Androl; 2008 May; 10(3):391-402. PubMed ID: 18385901
[TBL] [Abstract][Full Text] [Related]
17. Structure and Development of the List of Prohibited Substances and Methods.
Kinahan A; Budgett R; Mazzoni I
Med Sport Sci; 2017; 62():39-54. PubMed ID: 28571027
[TBL] [Abstract][Full Text] [Related]
18. Between medical treatment and performance enhancement: an investigation of how elite athletes experience Therapeutic Use Exemptions.
Overbye M; Wagner U
Int J Drug Policy; 2013 Nov; 24(6):579-88. PubMed ID: 23582632
[TBL] [Abstract][Full Text] [Related]
19. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
Vernec AR
Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
[TBL] [Abstract][Full Text] [Related]
20. Brief History of Anti-Doping.
Ljungqvist A
Med Sport Sci; 2017; 62():1-10. PubMed ID: 28571021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
